Home
  >  
Section 72
  >  
Chapter 71,185

A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial

Kulke, M.H.; Ruszniewski, P.; Van Cutsem, E.; Lombard-Bohas, C.; Valle, J.W.; De Herder, W.W.; Pavel, M.; Degtyarev, E.; Brase, J.C.; Bubuteishvili-Pacaud, L.; Voi, M.; Salazar, R.; Borbath, I.; Fazio, N.; Smith, D.; Capdevila, J.; Riechelmann, R.P.; Yao, J.C.

Annals of Oncology Official Journal of the European Society for Medical Oncology 30(11): 1846

2019


ISSN/ISBN: 0923-7534
PMID: 31987097
DOI: 10.1093/annonc/mdz219
Accession: 071184823

Download citation:  
Text
  |  
BibTeX
  |  
RIS

PDF emailed within 0-6 h: $19.90